HORIZON
A randomized double-blind, placebo-controlled, multicenter study assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease
- Stadium
- followup
- Middel
- TQJ230
- Populatie
- ASCVD
- Fase
- III
- First Patient In
- 13 mei 2020
- Last Patient In
- 8 juli 2022
- Last Patient Last Visit
- 31 maart 2026
National Lead
prof. dr. E.S.G. Stroes
Cardioloog
Studiedirecteur
